Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 2/2016

01-02-2016 | Letter to the Editor - Editorial

Management of rheumatoid arthritis: what happens and what does not happen in real life

Author: Daniel Aletaha

Published in: Rheumatology International | Issue 2/2016

Login to get access

Excerpt

In their article, Naranjo et al. [1] embarked on an important topic in contemporary treatment of rheumatoid arthritis. The authors not only reveal several factors associated with treatment modification in RA, but also find that clinical decision-making regarding treatment continuation, escalation, or de-escalation was not always consistent with the levels of measureable disease activity. …
Literature
1.
Naranjo A, Caceres L, Hernandez-Beriain JA, Francisco F, Ojeda S, Talaverano S et al (2015) Factors associated with the intensification of treatment in rheumatoid arthritis in clinical practice. Rheumatol Int 35(11):1851–1855. doi:10.​1007/​s00296-015-3332-z CrossRefPubMed
2.
Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J et al (2011) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70(3):404–413CrossRefPubMed
3.
Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P et al (2015) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 69(4):631–637. doi:10.​1136/​ard.​2009.​123919 CrossRef
4.
Studenic P, Radner H, Smolen JS, Aletaha D (2012) Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum 64(9):2814–2823CrossRefPubMed
5.
Aletaha D, Smolen JS (2006) Remission of rheumatoid arthritis: Should we care about definitions? Clin Exp Rheumatol 24(6 Suppl 43):S-51
6.
7.
Dale J, Purves D, McConnachie A, McInnes I, Porter D (2014) Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. Arthritis Care Res (Hoboken) 66(1):19–26CrossRef
Metadata
Title
Management of rheumatoid arthritis: what happens and what does not happen in real life
Author
Daniel Aletaha
Publication date
01-02-2016
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 2/2016
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-015-3402-2

Other articles of this Issue 2/2016

Rheumatology International 2/2016 Go to the issue

Erratum

Erratum to: Bowel perforations in a patient affected by Churg–Strauss syndrome under high-dose steroid treatment: will alternative drugs reduce risk of surgery?

Short Communication - Validation Studies

Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis

Case Based Review - Cases with a Message

Intermediate-term follow-up of chronically ill patients with digital ischemia treated with peripheral digital sympathectomy

Original Article - Health Services Research

Risk factors associated with the occurrence of proximal humerus fractures in patients with rheumatoid arthritis: a custom strategy for preventing proximal humerus fractures

Short Communication - Education

The educational needs of people with systemic sclerosis: a cross-sectional study using the Dutch version of the Educational Needs Assessment Tool (D-ENAT)

Original Article - Observational Research

Splenectomy increases the subsequent risk of systemic lupus erythematosus
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits